Table 2. Adverse events G3/G4 among patients and according to age.
| Variable | All cases | Group 1 (age <65 yr) | Group 2 (age ≥65 yr) | p-value | |
|---|---|---|---|---|---|
| Patients | 283 | 211 (74.6) | 72 (25.4) | - | |
| Patients with G3/G4 AEs | 27 (9.5) | 19 (9.0) | 8 (11.1) | 0.599 | |
| BEV related G3/G4 AEs* | |||||
| Hematologic | 5 (1.97) | 4 (1.9) | 1 (1.4) | 0.631 | |
| Gastrointestinal (bowel perforation, subocclusion, volvulus) | 7 (2.4) | 6 (2.8) | 1 (1.4) | 0.684 | |
| Venous thromboembolic events | 6 (2.1) | 4 (1.9) | 2 (2.8) | 0.643 | |
| Arterial thromboembolic events/stroke/ictus | 1 (0.3) | 1 (0.5) | 0 | 0.748 | |
| Hypertension | 6 (2.1) | 5 (2.3) | 1 (1.4) | 0.535 | |
| Proteinuria | 8 (2.8) | 4 (1.9) | 4 (5.6) | 0.112 | |
| Chronic kidney failure† | 8 (2.8) | 3 (1.4) | 5 (7) | 0.627 | |
| Bleeding | 1 (0.3) | 1 (0.4) | 0 | 0.554 | |
| Wound healing complication | 3 (1) | 2 (0.9) | 1 (1.4) | 0.753 | |
| Fistula/abscess | 1 (0.3) | 0 | 1 (1.4) | 0.082 | |
| Congestive heart failure | 0 | 0 | 0 | NA | |
| Posterior reversible encephalopathy syndrome | 0 | 0 | 0 | NA | |
| Arthralgia | 1 (0.3) | 0 | 1 (1.4) | 0.082 | |
| Liver (high liver enzymes) | 1 (0.3) | 1 (0.4) | 0 | 0.554 | |
| Main reason for BEV discontinuation | |||||
| Disease progression | 96 (34) | 70 (33.1) | 26 (36.1) | 0.488 | |
| Treatment related AEs | 17 (6) | 10 (4.7) | 7 (9.7) | 0.355 | |
| Worsening comorbidity | 0 | 0 | 0 | NA | |
| Other | 1 (0.3) | 1 (0.5) | 0 | 0.956 | |
Values are presented as number (%).
BEV, bevacizumab; AE, adverse event; eGFR CDK-EPI, estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation.
*Patient might have more than 1 AE; †Expressed as eGFR CDK-EPI <60 mL/min.